Clinical trials: LPA
Diabetic Kidney Disease, Diabetes Mellitus, Type 2
Possible Ameliorating Effect of N- Acetylcysteine (NAC) on Type-II Diabetes Induced Nephropathy
The study is focused on the possible improving effect of N-acetylcysteine on nephropathy of type-2 diabetic patients. Study design: Prospective clinical based study.
- Conditions
- Diabetic Kidney Disease, Diabetes Mellitus, Type 2, Diabetic Nephropathies
- Trial name
- (NAC) (NCT04531163)
- Testing
- N Acetylcysteine
- Where
- Egypt
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Al-Azhar University
Lifestyle Risk Reduction, Cholesterol, Elevated
Effect of a Customised Lifestyle Medicine Strategy on Lowering Blood Lipid Levels in Indian Physicians
Lifestyle medicine is a medical specialty that uses evidence-based therapeutic interventions to prevent, treat, and reverse chronic conditions.
- Conditions
- Lifestyle Risk Reduction, Cholesterol, Elevated, LDL Hyperlipoproteinemia, Hypertension
- Trial name
- CLIP (NCT06420817)
- Testing
- Indian version of a 'Portfolio' diet, Physical Activity, Intermittent fasting
- Where
- India
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Jubilee Mission Medical College and Research Institute
Healthy Participants, Elevated Lp(a)
SAL0137 Phase I Study in in Healthy Participants With or Without Elevated Lp(a)
This study is divided into 3 parts: Part A, Part B, and Part C. Part A is a randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of…
- Trial name
- NCT07745114
- Testing
- Single Ascending Dose, Once Daily (QD), Multiple Ascending Dose (MAD)
- Where
- China
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Elevated Lipoprotein(a)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS APO(a)-LRx in Healthy Volunteers With Elevated Lipoprotein(a)
The purpose is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IONIS APO(a)-LRx (ISIS 681257) given to healthy volunteer subjects.
- Trial name
- NCT02414594
- Testing
- IONIS-APO(a)-LRx, Sterile Normal Saline (0.9% NaCl)
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ionis Pharmaceuticals, Inc.
Hypercholesterolemia, Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia
Elevated Lipoprotein(a) in Hospital Staff
The objective of this study is to investigate the prevalence of elevated Lp(a) in the working general population.
- Conditions
- Hypercholesterolemia, Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia, Cardiovascular Diseases
- Trial name
- LPACO (NCT06304415)
- Where
- Singapore
- Volunteers
- 2,800 people, healthy volunteers welcome
- Sponsor
- Changi General Hospital
Elevated Lipoprotein(a), Cardiovascular Diseases
Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Clopidogrel
This is a single center, open label, single sequence, two treatment, two-period drug-drug interaction study to evaluate the effect of multiple doses of ISIS 681257 on the pharmacokinetics of multiple doses of clopidogrel
- Trial name
- NCT03392051
- Testing
- ISIS 681257, Clopidogrel
- Where
- Canada
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Akcea Therapeutics
Healthy, Heart Disease
Family Research Study: Metabolism of Fats and Proteins in Specific Ethnic Groups
The purpose of this study is to determine whether lipoprotein(a), also called Lp(a), is a risk factor for cardiovascular (heart) disease. Lipoproteins are tiny particles that circulate in the blood.
- Trial name
- NCT00853775
- Testing
- No intervention, observational study
- Where
- United States
- Volunteers
- 325 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Cardiovascular Disease
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)
This is a first-in-human, randomized, double-blind, placebo-controlled, single ascending dose study in subjects with elevated plasma Lipoprotein(a) [Lp(a)].
- Trial name
- NCT03626662
- Testing
- AMG 890
- Where
- 9 sites in United States, Australia
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Amgen
Cardiovascular Diseases, Atherosclerosis Cardiovascular Disease
Lipoprotein (a) and Vascular Regenerative Cell Content
Lp(a)-VRCE is an observational, cross sectional study looking at vessel reparative stem cell content in people with and without elevated lipoprotein (a) [Lp(a)].
- Conditions
- Cardiovascular Diseases, Atherosclerosis Cardiovascular Disease, Ischemic Heart Disease, Dyslipidemia
- Trial name
- Lp(a)-VRCE (NCT06626659)
- Where
- 2 sites in Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Canadian Medical and Surgical Knowledge Translation Research Group
Sedentary Lifestyle, Risk Factor, Cardiovascular
Assessing the Effects Of Treadmill On LPA, Sitting Time, and Cardiovascular Risk
The purpose of this study is to: 1. Evaluate the relative efficacy of a treadmill desk intervention on light physical activity and sitting behaviors at work over four weeks; 2.
- Trial name
- NCT03236597
- Testing
- Treadmill desk
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of Minnesota